On 28 October 2026 the US Department of Health and Human Services (HHS) announced that compounding pharmacies may, for now, supply six peptides by prescription. ABC News reported the decision the same day. This is our summary of the report, followed by the MedBridge Global team’s view on what it means for clinicians. Read the full story on ABC News.

What HHS announced

The policy is temporary and covers six peptides: BPC-157, TB-500, epitalon, MOTS-c, KPV and semax. All six have been promoted online for tissue repair, skin appearance or longevity. HHS presents the decision as a matter of patient safety and choice, giving patients a regulated alternative to black-market sellers. The report does not say how long the policy will last.

The conditions attached

  • Each prescription must be for a specific, named patient.
  • Ingredients must be traceable to their source.
  • Products must pass quality testing.
  • Compounders must report safety information.

HHS is clear that the policy is not FDA approval, and that it does not establish that any of the six peptides is safe or effective.

How we got here

  • In 2023 the FDA classified 19 peptides as unsafe to compound. HHS Secretary Robert F. Kennedy Jr. has previously called that decision illegal.
  • In July 2026 an independent FDA advisory panel voted to recommend adding the six peptides to the 503A bulks list, the list of ingredients compounding pharmacies can use for individual prescriptions.

What the evidence says

The report notes that there are no published clinical trials showing that these six peptides work in humans for any condition. Doctors cited in the report also warn that products from unregulated sellers may not contain what the label says, and may be contaminated or wrongly dosed. Peptides as a class are not new to medicine: insulin and the GLP-1 drugs are peptides that reached patients through full clinical trials and FDA approval.

The MedBridge Global team’s view

We welcome a route that moves patients away from “research use only” vials and towards licensed pharmacies with testing and safety reporting. We have written before about the harm the gray market is doing to patients, and a regulated supply is a real step forward.

But access is not evidence. A prescription from a compounding pharmacy does not make a peptide proven, and the responsibility for that prescription now sits squarely with the clinician who writes it. For prescribers, that means:

  • Knowing the pharmacology and the limits of the evidence for each peptide before prescribing it, and explaining both honestly to patients.
  • Choosing a licensed, accredited compounding pharmacy that can show its sourcing and testing.
  • Selecting patients carefully, documenting consent and monitoring for adverse effects.
  • Reporting adverse events, so the safety data this policy depends on is actually collected.

The policy is temporary, and what comes next will depend partly on how responsibly these peptides are prescribed now. For more on where compounding regulation is heading, read our Q&A with Nate Hill of Strive Pharmacy. Our Peptide Master Certification is built to give prescribers that grounding in evidence, dosing, monitoring and regulation.

Sources